TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) reached a new 52-week high on Tuesday after Bank of America raised their price target on the stock from $17.00 to $20.00. Bank of America currently has an underperform rating on the stock. TG Therapeutics traded as high as $57.98 and last traded at $57.7660, with a volume of 685159 shares changing hands. The stock had previously closed at $55.47.
A number of other research analysts have also weighed in on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $83.00 price target on shares of TG Therapeutics in a research note on Monday, June 22nd. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of TG Therapeutics in a research report on Monday. Weiss Ratings raised shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. Finally, Zacks Research upgraded shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $52.17.
Get Our Latest Research Report on TGTX
Hedge Funds Weigh In On TG Therapeutics
TG Therapeutics Trading Up 5.0%
The business’s 50 day simple moving average is $44.35 and its two-hundred day simple moving average is $35.58. The stock has a market cap of $8.91 billion, a P/E ratio of 20.31, a PEG ratio of 2.18 and a beta of 1.60. The company has a quick ratio of 5.12, a current ratio of 5.81 and a debt-to-equity ratio of 1.28.
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). The business had revenue of $204.92 million for the quarter, compared to the consensus estimate of $200.33 million. TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The company’s revenue was up 69.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.03 earnings per share. As a group, analysts expect that TG Therapeutics, Inc. will post 1.51 EPS for the current year.
About TG Therapeutics
TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.
In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.
Featured Articles
- Five stocks we like better than TG Therapeutics
- AI Insider Activity: Are Sales Across 3 Key Stocks Noteworthy or Just Noise?
- 3 Quiet AI Revenue Accelerators With Sales Growth Outpacing Peers
- Top 135 Best Locally Owned BBQ Supply Stores in the U.S., According to Survey [2026]
- Silicon Starvation: Amazon Feasts on Legacy GPUs
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
